Stock C1P CONSUN PHARMACEUTICAL GROUP LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Consun Pharmaceutical Group Limited Deutsche Boerse AG

Equities

C1P

KYG2524A1031

Market Closed - Deutsche Boerse AG
Other stock markets
 10:54:49 2024-05-24 EDT 		5-day change 1st Jan Change
0.76 EUR +14.29% Intraday chart for Consun Pharmaceutical Group Limited +11.76% +43.40%
05-24 Consun Pharmaceutical Group Limited Announces Special Dividend, Payable on 21 June 2024 CI
05-24 Consun Pharmaceutical Group Announces Special Dividend on 10th Anniversary of Joining HK Bourse MT

Summary

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
  • Overall, and from a short-term perspective, the company presents an interesting fundamental situation.

Strengths

  • Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
  • The group's activity appears highly profitable thanks to its outperforming net margins.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • Its low valuation, with P/E ratio at 5.86 and 5.18 for the ongoing fiscal year and 2025 respectively, makes the stock pretty attractive with regard to earnings multiples.
  • The stock, which is currently worth 2024 to 0.84 times its sales, is clearly overvalued in comparison with peers.
  • The company's share price in relation to its net book value makes it look relatively cheap.
  • This company will be of major interest to investors in search of a high dividend stock.
  • Analysts remain confident with respect to the group's activity and, more often than not, have revised upwards their earnings per share estimates.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • Historically, the company has been releasing figures that are above expectations.

Weaknesses

  • The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
  • The overall consensus opinion of analysts has deteriorated sharply over the past four months.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
CONSUN PHARMACEUTICAL GROUP LIMITED Stock Consun Pharmaceutical Group Limited
+43.40% 683M -
SUN PHARMACEUTICAL INDUSTRIES LTD. Stock Sun Pharmaceutical Industries Ltd.
+18.04% 42.95B
B-
OTSUKA HOLDINGS CO., LTD. Stock Otsuka Holdings Co., Ltd.
+16.92% 21.38B
B+
SANDOZ GROUP AG Stock Sandoz Group AG
+18.33% 15.05B -
CIPLA LIMITED Stock Cipla Limited
+19.27% 14.45B
B+
ZYDUS LIFESCIENCES LIMITED Stock Zydus Lifesciences Limited
+56.12% 13.04B
B
THE MEDICINES COMPANY Stock The Medicines Company
-0.05% 6.79B - -
ONO PHARMACEUTICAL CO., LTD. Stock Ono Pharmaceutical Co., Ltd.
-10.73% 6.72B
B+
STADA ARZNEIMITTEL Stock STADA Arzneimittel
-8.87% 5.73B - -
ASPEN PHARMACARE HOLDINGS LIMITED Stock Aspen Pharmacare Holdings Limited
+11.21% 5.47B
B+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. 1681 Stock
  4. C1P Stock
  5. Ratings Consun Pharmaceutical Group Limited